Pharmanovia Expands Its Neurology Portfolio with XADAGO®
Pharmanovia, a global pharmaceutical company, has announced a significant development in its neurology segment by acquiring exclusive rights to XADAGO® (safinamide), an important add-on treatment for adult patients suffering from idiopathic Parkinson's disease. This licensing agreement marks an exciting step forward for Pharmanovia as it aims to improve the quality of life for those affected by this progressive neurodegenerative condition.
New Licensing Agreement for Parkinson's Treatment
The licensing agreement for XADAGO® has been secured from Zambon, an Italian multinational pharmaceutical company known for its commitment to innovative healthcare solutions. Through this partnership, Pharmanovia will take over the rights previously held by CSL Seqirus in Australia and New Zealand. As a result, Pharmanovia will be solely responsible for regulatory and commercial activities within these regions, in addition to assuming the role of Marketing Authorization Holder (MAH).
Insights on Parkinson's Disease
Parkinson’s disease has become the fastest-growing neurological condition in the world, according to information from health organizations. This growth underlines the urgent need for effective treatments that can help manage symptoms and enhance the quality of life for patients. The acquisition of XADAGO® exemplifies Pharmanovia's dedication to addressing this pressing health issue.
Pharmanovia's Commitment to Patient Care
In a recent statement, Pharmanovia CEO, James Burt, expressed enthusiasm for the latest licensing agreement. He noted, "Today’s announcement brings us a new chemical entity (NCE), with clear synergies to our existing CNS portfolio. In XADAGO® (safinamide) we have an important medicine helping patients to control Parkinson's symptoms, and we’re excited to use our platform to continue to bring this medicine to patients." This statement highlights the company's ongoing commitment to offering quality healthcare solutions that can significantly improve patient outcomes.
Trust from Collaborators
Furthermore, Burt acknowledged the trust shown by CSL Seqirus in handing over the product, which he believes reinforces Pharmanovia's ability as a core commercial partner in the region. "We aim to leverage our experience in central nervous system therapeutics to enhance the reach of XADAGO® and make a positive impact on patients' lives," he added.
Collaboration with CSL Seqirus
Danielle Dowell, the Executive Director for Commercial Operations at CSL Seqirus, commended Pharmanovia's strong capabilities and presence in both the Australian and New Zealand markets. She remarked, "Pharmanovia has experience in bringing differentiated products to patients, and we’re confident that they will leverage their portfolio to help reach even more people living with Parkinson’s. This partnership is a testament to the innovative approaches both companies are taking to address patient needs effectively.
About Pharmanovia
Pharmanovia focuses on lifecycle management, striving to make medicines adaptable for future challenges to improve global patient lives. Their efforts include rediscovering, repurposing, or re-engineering iconic medicine brands to enhance outcomes and experiences for patients. Operating in over 160 countries, Pharmanovia places a high value on delivering high-quality solutions sustainably and ethically across four key therapeutic areas: Endocrinology, Neurology, Cardiovascular, and Oncology.
About CSL Seqirus
CSL Seqirus, a subsidiary of CSL (ASX: CSL), stands as one of the world’s largest providers of influenza vaccines. With a strong commitment to public health, the company plays a crucial role in global pandemic preparedness and offers a diverse portfolio of influenza vaccines in over 20 countries. Their initiatives support the Australian market through local facilities that manufacture vaccines and unique medicines, demonstrating their dedication to various health needs, including those related to allergies, cardiovascular diseases, and neurological conditions.
Frequently Asked Questions
What is the significance of Pharmanovia acquiring XADAGO®?
This acquisition enhances Pharmanovia's neurology portfolio, allowing them to provide critical treatment options for Parkinson's disease more effectively.
How will Patients benefit from Pharmanovia’s new agreement?
Patients will have better access to an important medicine that can help control Parkinson’s symptoms due to Pharmanovia’s dedicated efforts to promote XADAGO®.
What is Pharmanovia's main focus as a healthcare company?
Pharmanovia aims to improve patient outcomes through lifecycle management of medicines, focusing on repurposing and enhancing established drug brands.
How does CSL Seqirus fit into this agreement?
CSL Seqirus transferred the rights to XADAGO® to Pharmanovia, reflecting a partnership built on mutual trust and a shared vision for addressing patient needs.
What are Pharmanovia’s therapeutic areas of focus?
Pharmanovia primarily concentrates on Endocrinology, Neurology, Cardiovascular, and Oncology therapeutic areas, working to deliver effective healthcare solutions globally.
